Figure 4: RBCs From db/db Mice Impair Cardiac Post-Ischemic Recovery via an Arginase-Dependent Pathway

(A) Hearts from WT mice were given RBCs from db/db mice incubated with vehicle (n = 5), Nω-hydroxy-nor-L-arginine (nor-NOHA) 1 mmol/l (n = 8) or 3 mmol/l (n = 4). (B) Hearts from WT mice were given RBCs from db/db mice incubated with vehicle (n = 5) or ABH (1 mmol/l, n = 4). (C) Hearts from db/db mice were given KH buffer with either vehicle (n = 8) or nor-NOHA (1 mmol/l, n = 5). (D) Hearts from WT mice were given RBCs from WT mice incubated with vehicle (n = 6), the arginase inhibitor nor-NOHA (1 mmol/l, n = 10), nor-NOHA (3 mmol/l, n = 8) or L-NAME (0.1 mmol/l) + nor-NOHA (1 mmol/l, n = 6). (E) Hearts from db/db mice were given RBCs from WT mice incubated with vehicle (n = 5), nor-NOHA (1 mmol/l, n = 5) or L-NAME (0.1 mmol/l) + nor-NOHA (1 mmol/l, n = 5). Post-ischemic LVDP is expressed as percentage recovery from the pre-ischemic level. Significant differences between treatments were analyzed using 2-way analysis of variance including all time points; *p < 0.05 and ***p < 0.001. Abbreviations as in Figures 1, 2, and 3.